Work

A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps1126

Authors: Steven J. Isakoff, Sara M. Tolaney, Nadine M. Tung, Sylvia Adams, Hatem Hussein Soliman, Elena F Brachtel, Karleen R. Habin, Louisa J Bauer, Leif W. Ellisen, Mariano Severgnini, William Thomas Barry, Doris Peterkin

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, University of South Florida, Moffitt Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2624253981

Cites:

Cited by: 14

Related to: 10